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step in the process of validation of foam sclerotherapy
as an independent, safe and effective treatment of var-
icose veins. Unfortunately few similar randomised tri-
als have been published in this field. The authors aimed
at assessingwhether 1%POL gives similar outcomes to
3% POL in foam sclerotherapy of the GSV. The conclu-
sions in this paper are slightly different from those of
Dutch authors in a recent publication on the same sub-
ject, who considered that better outcomes were ob-
tained with 3% foam.1 This difference may be due to
variability in preparing and injecting sclerosant foam,
in the compression regime, as well as duplex and clin-
ical assessments of outcome. The data in the Dutch pa-
per in fact show no statistical difference in the rate of
saphenous occlusion at one year of follow-up (69.5%
in the 1% vs. 80, 1% in the 3% group). Despite this, the
authors found that the patients thought a better out-
come was obtained by the use of 3% foam.
The ‘‘Turbofoam’’ machine was employed by
Dr Hamel-Desnos et al. as a means of standardising
treatment between centres and this may produce dif-
ferent foam from the commonly used Tessari method.
Recently Myers et al.2 reported better outcome with
1.5% Sodium TetradecylSulfate sclerosant foam than
with either stronger or weaker foam. However, these
data were obtained from a clinical series rather than
in an RCT. Use of stronger foams may be associated
with a higher number of adverse events, particularly
superficial phlebitis and skin pigmentation. Therefore
it is very valuable to have data which support the use
of 1% foam. If this necessitated injection of increased
volumes of foam then some of the advantage would
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thromboembolism. As well as providing some an-
swers, this study also shows that many aspects of prac-
tice in sclerotherapy are based on the personal
preference of sclerotherapists rather than hard clinical
data. Much more work will be required to address the
many other aspects of sclerotherapy that deserve the
detailed attention shown in this paper. For example,
what should we do with saphenous trunks larger in
size than those managed by Hamel-Desnos et al.? Do
weneedahigherconcentrationof sclerosantor agreater
volume and should we apply compression?Most foam
sclerotherapypractitioners recognise that the size of the
treated veins still represents one of the main factors
which affect the results of foam sclerotherapy.2e5
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